Cargando…
Drug Retention Rates and Treatment Discontinuation among Anti-TNF-α Agents in Psoriatic Arthritis and Ankylosing Spondylitis in Clinical Practice
Objective. The study aim was to determine treatment persistence rates and to identify causes of discontinuation in psoriatic arthritis (PsA) and ankylosing spondylitis (AS) patients in clinical practice. Methods. Patients treated with adalimumab (ADA), etanercept (ETA), or infliximab (INF) were retr...
Autores principales: | Fabbroni, Marta, Cantarini, Luca, Caso, Francesco, Costa, Luisa, Pagano, Veronica Anna, Frediani, Bruno, Manganelli, Stefania, Galeazzi, Mauro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4119698/ https://www.ncbi.nlm.nih.gov/pubmed/25110401 http://dx.doi.org/10.1155/2014/862969 |
Ejemplares similares
-
Secukinumab for ankylosing spondylitis and psoriatic arthritis
por: Lubrano, Ennio, et al.
Publicado: (2016) -
Real-Life Retention Rates and Reasons for Switching of Biological DMARDs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
por: Bhushan, Vandana, et al.
Publicado: (2021) -
Drug Retention and Safety of Secukinumab in a Real-World Cohort of Ankylosing Spondylitis and Psoriatic Arthritis Patients
por: Moskal, Mateusz, et al.
Publicado: (2022) -
Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis
por: Maneiro, Jose Ramon, et al.
Publicado: (2015) -
Golimumab: A novel human anti-TNF-α monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis
por: Kay, Jonathan, et al.
Publicado: (2010)